Citadel Advisors
SANA icon

Citadel Advisors’s Sana Biotechnology SANA Stock Holding History

Citadel Advisors’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$563K Sell
161,178
-407,912
-72% -$1.31M ﹤0.01% 9572
2026
Q1 		$1.64M Buy
569,090
+555,549
+4,103% +$2.19M ﹤0.01% 6533
2025
Q4 		$55.1K Sell
13,541
-6,538,436
-100% -$29.3M ﹤0.01% 11993
2025
Q3 		$23.3M Buy
6,551,977
+3,596,930
+122% +$13M ﹤0.01% 2141
2025
Q2 		$8.07M Sell
2,955,047
-447,564
-13% -$923K ﹤0.01% 3343
2025
Q1 		$5.72M Buy
3,402,611
+2,197,074
+182% +$6.14M ﹤0.01% 3665
2024
Q4 		$1.97M Buy
1,205,537
+1,026,243
+572% +$3.06M ﹤0.01% 5663
2024
Q3 		$746K Buy
179,294
+119,919
+202% +$630K ﹤0.01% 7417
2024
Q2 		$324K Sell
59,375
-1,827,781
-97% -$14.6M ﹤0.01% 8983
2024
Q1 		$18.9M Buy
1,887,156
+1,847,280
+4,633% +$13.8M ﹤0.01% 2129
2023
Q4 		$163K Sell
39,876
-245,596
-86% -$905K ﹤0.01% 10262
2023
Q3 		$1.1M Buy
285,472
+166,040
+139% +$892K ﹤0.01% 6356
2023
Q2 		$712K Sell
119,432
-1,469,949
-92% -$8.47M ﹤0.01% 7160
2023
Q1 		$5.2M Buy
1,589,381
+737,578
+87% +$2.95M ﹤0.01% 3741
2022
Q4 		$3.36M Sell
851,803
-335,609
-28% -$1.64M ﹤0.01% 4555
2022
Q3 		$7.13M Buy
1,187,412
+1,119,195
+1,641% +$8.08M ﹤0.01% 3290
2022
Q2 		$439K Buy
68,217
+32,950
+93% +$210K ﹤0.01% 8940
2022
Q1 		$291K Sell
35,267
-163,896
-82% -$1.33M ﹤0.01% 10660
2021
Q4 		$3.08M Buy
+199,163
New +$3.84M ﹤0.01% 5283
2021
Q3 		– Sell
-59,693
Closed -$1.25M – 14538
2021
Q2 		$1.17M Sell
59,693
-51,765
-46% -$1.17M ﹤0.01% 7934
2021
Q1 		$3.73M Buy
+111,458
New +$3.63M ﹤0.01% 4930

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Citadel Advisors's SANA Position: Q2 2026 in Review

Citadel Advisors reduced its Sana Biotechnology (SANA) stake by 72% in Q2 2026, selling an estimated $1.31M and leaving 161,178 shares worth $563K. The position accounts for ﹤0.01% of the portfolio, ranked #9572.

Citadel Advisors first reported a position in SANA in Q1 2021 and has held it in 21 quarters since. The position peaked at $23.3M in Q3 2025. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • Citadel Advisors held 161,178 shares of Sana Biotechnology worth $563K as of Q2 2026.
  • Citadel Advisors sold 407,912 Sana Biotechnology shares in Q2 2026, an estimated $1.31M.
  • Sana Biotechnology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9572 holding.
  • Citadel Advisors first reported a position in Sana Biotechnology in Q1 2021 and has held it in 21 quarters since.
  • Citadel Advisors's Sana Biotechnology position peaked at $23.3M in Q3 2025.
  • 211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.